Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.50 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | XPO1 | O14980 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.36 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | FLT4 | P35916 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12347531 | 0.87 | RAPGEF4 (0.47) | RAPGEF4MAPTXPO1P2RX1SMN1; SMN2 | |
| SCHEMBL16564651 | 0.83 | POLB (0.37) | RAPGEF4TAS2R14SMN1; SMN2ALDH1A1 | |
| SCHEMBL13181873 | 0.81 | RAPGEF4 (0.55) | RAPGEF4TAS2R14MAPTXPO1SRC | |
| SCHEMBL6575628 | 0.80 | RAPGEF4 (0.42) | RAPGEF4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL16564657 | 0.80 | RAPGEF4 (0.37) | RAPGEF4MAPTCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21571898 | 0.80 | EGFR (0.40) | RAPGEF4MAPTXPO1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10104509 | 0.78 | RAPGEF4 (0.49) | RAPGEF4TAS2R14MAPTXPO1SRC | |
| SCHEMBL29030467 | 0.78 | RAPGEF4 (0.41) | RAPGEF4MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL11677821 | 0.78 | RAPGEF4 (0.52) | RAPGEF4TAS2R14MAPTXPO1SRC | |
| SCHEMBL17681768 | 0.78 | RAPGEF4 (0.52) | RAPGEF4TAS2R14MAPTXPO1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598446-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | RAPGEF4 2579/4885TAS2R14 977/4885MAPT 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.